1
|
Rubira L, Leenhardt F, Perrier C, Pinguet F. [Securing the patient's care path receiving oral anticancer therapy: Experimentation around a pharmaceutical hospital-to-community liaison]. Ann Pharm Fr 2021; 79:558-565. [PMID: 33548278 DOI: 10.1016/j.pharma.2021.01.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 01/25/2021] [Accepted: 01/27/2021] [Indexed: 11/26/2022]
Abstract
Due to the increasing prescription of oral anticancer therapies, the inpatient care pathway has shifted to an outpatient care pathway. This transformation requires an interdisciplinary coordination to provide a continuum of care and ensure therapeutic monitoring, as well as patient safety. To better support patients on oral anticancer therapies, a task group named "hospital-to-community pharmacist coordination" has been set up to create tools aiming at standardising the information exchanged between ambulatory and hospital pharmacists. A retrospective study examined the utilisation of the tools over a period of one year. The task group identified the expectations of all parties regarding the care pathways of patients undergoing oral chemotherapy, which lead to the creation of computerised exchange tools (integrated into the computerised patient's medical file). Over the course of this study, the cancer centre's pharmaceutical team contacted 425 ambulatory pharmacists regarding the prescription of oral chemotherapy to patients. Forty-two follow-ups from ambulatory pharmacists, gathering information on 34 patients, were submitted to the cancer centre pharmacists (7,7%). These first follow-ups allowed pharmaceutical responses regarding patient compliance, drug interaction and toxicities.
Collapse
Affiliation(s)
- L Rubira
- Service de pharmacie, institut du cancer de Montpellier, CLCC, 208 rue des Apothicaires, 34298 Montpellier cedex 5, France
| | - F Leenhardt
- Service de pharmacie, institut du cancer de Montpellier, CLCC, 208 rue des Apothicaires, 34298 Montpellier cedex 5, France; Service de pharmacocinétique, faculté de pharmacie de Montpellier, université de Montpellier, Montpellier, France.
| | - C Perrier
- Service de pharmacie, institut du cancer de Montpellier, CLCC, 208 rue des Apothicaires, 34298 Montpellier cedex 5, France
| | - F Pinguet
- Service de pharmacie, institut du cancer de Montpellier, CLCC, 208 rue des Apothicaires, 34298 Montpellier cedex 5, France
| |
Collapse
|
2
|
Carbasse C, Leenhardt F, Jacot W, Perrier C, Pinguet F, Viala M. CN20 Oral targeted therapy dose adaptation in geriatric cancer patients: A real life French cohort. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Solassol I, Pinguet F, Quantin X. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules 2019; 9:biom9110668. [PMID: 31671561 PMCID: PMC6921037 DOI: 10.3390/biom9110668] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 10/23/2019] [Accepted: 10/25/2019] [Indexed: 12/31/2022] Open
Abstract
Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alterations, in particular in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene. Gefitinib, erlotinib, afatinib, and osimertinib are TK inhibitors (TKIs) that specifically target EGFR and are currently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first line treatment for sensitive EGFR-mutant patients. However, these four drugs are associated with severe adverse events (AEs) that can significantly impact patient health-related quality of life and patient monitoring. EGFR-TKIs are commonly used together with other types of medication that can substantially interact. Here, we review approaches used for the management of TKI-AEs in patients with advanced NSCLC to promote the benefits of treatments and minimize the risk of TKI treatment discontinuation. We also consider potential TKI–drug interactions and discuss the usefulness of plasma concentration monitoring TKIs based on chromatographic and mass spectrometry approaches to guide clinical decision-making. Adjusting the most appropriate therapeutic strategies and drug doses may improve the performance therapy and prognosis of patients with advanced EGFR-mutated NSCLC.
Collapse
Affiliation(s)
- Isabelle Solassol
- Unité de Recherche Translationnelle, Institut du Cancer de Montpellier (ICM), 34000 Montpellier, France.
- Département de Pharmacie, Institut du Cancer de Montpellier (ICM), 34000 Montpellier, France.
| | - Frédéric Pinguet
- Département de Pharmacie, Institut du Cancer de Montpellier (ICM), 34000 Montpellier, France.
| | - Xavier Quantin
- Service d'Oncologie Médicale, Institut du Cancer de Montpellier (ICM), IRCM, INSERM, Univ. Montpellier, 34000 Montpellier, France.
| |
Collapse
|
4
|
Correard F, Blanc-léger F, Roux C, Lobrot F, Pinguet F, Pourrat X, Pourroy B, Donamaria C, Kopferschmitt J. Complementary medicine and cancer: A French multicenter survey. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e23127] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e23127 Background: There have been few reports about Complementary Therapy (TC) use in outpatients who are on active cancer chemotherapy in France. TC may interact with cancer treatments, reduce efficacy, or enhance adverse effects. Methods: This is a cross-sectional survey on TC use in 7 French hospitals (outpatient chemotherapy, conventional hospitalization and medical consultation departments). Eligible patients had to be followed for a cancer and be over 18. Results: 415 patients answered the questionnaire. 54% were female, More than 80% of patients were over 50. 230 patients (55.4%) reported using TCs. TCs were prescribed or recommended for 180 patients. The main TC users were patients with melanoma or other cutaneous cancer (90% of them) and bone and soft tissues sarcomas (86% of them). Most patients used only one TC (52.6%). The most used TCs were Phytotherapy (48%), Homeopathy (40%), supplemental dietary (35%) and aromatherapy (21%). 110 patients (47, 8% of patients with TC) used phytotherapy. The most used plants (≥5% of use) were: Curcuma and its derivative curcumine (13.9%), desmodium (7.4%), thymus (5%). 93 patients used homeopathy (40.4% of patients with TC). Only 48 patients used aromatherapy (20.9% of patients with TCM or 11.6% of the whole population). 81 patients used Supplemental dietary (35.2% of patients with TCM or 19.5% of the whole population). Only 27 patients used oligo-elements (11.7% of patients with TCM or 6.5% of the whole population),). Interestingly, 20% of patients declared to use others TCs (Physical activity, Acupuncture, Somatotherapy, Sophrology, Chinese traditional Medecine, Specific diet, Psychotherapy…). Patient who used TC were mainly under chemotherapy regimen.For each TC, most patients considered that they were useful or very useful. The main reasons for using TCs were “Wellbeing and psychological support” (35.8%), “Clinical symptoms and chemotherapy tolerance improvement” (34.6%) and “Treatment of cancer” (17.7%). Conclusions: To protect cancer patients from the potential hazard of combining their cancer treatment with TCs, patients should systematically be encouraged to report their TC use, while oncologists and pharmacists should be trained on evidence of TC, and patient guidance for a safer TC use.
Collapse
Affiliation(s)
- Florian Correard
- Assistance Publique Hôpitaux de Marseille, Division of Pharmacy, Marseille, France
| | | | | | | | - Frédéric Pinguet
- Institut du Cancer de Montpellier, Division of Pharmacy, Montpellier, France
| | - Xavier Pourrat
- CHRU Hôpitaux de Tours, Division of Pharmacy, Chambray-Lès-Tours, France
| | - Bertrand Pourroy
- Assistance Publique Hôpitaux de Marseille, Division of Pharmacy, Marseille, France
| | | | | |
Collapse
|
5
|
Roché H, Venat-Bouvet L, Debled M, Jacot W, Suc E, Dalenc F, Molnar-Stanciu D, Dohollou N, Franck D, Ferrer C, Laharie-Mineur H, Lavau-Denes S, Massabeau C, Mauries V, Robert J, Pinguet F, Marquet P, Evrard A, Chatelut E, Filleron T. Abstract P3-12-10: First 6-month report of the longitudinal PHACS study ( Pharmacology and Hormonotherapy (HT) for Adjuvant breast Cancer (BC) Study, NCT01127295). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-12-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BC is a hormone-dependent disease for 75% of pts. HT is used in both adjuvant and metastatic settings for hormone–receptor (HR) positive tumors. In adjuvant situation, a 5-year HT period at least is recommended. Side-effects (SE) frequently alter quality of life and compliance, reducing the well-known benefits in risks of relapses and specific deaths. Underlying mechanisms are well understood for estrogen deprivation-induced events such as hot flashes, but little is known on arthralgia under aromatase inhibitors (AI). So, pharmacogenomics (PG), pharmacokinetics (PK), potential medications interactions are of value to explain individual drugs exposures, possible related side-effects and compliance to treatment.
Methods: We performed a prospective, multicenter, longitudinal study registering early clinical outcomes and SE during the first 3 years of adjuvant HT with tamoxifen (T) or AI. All tumors expressed at least one HR (>10%). The choice of HT molecule and one-drug or sequential treatment were left to the investigator. Pts were followed every 6 months with clinical examination by the referent oncologist and PK sampling each time. Biologic research consisted in PG investigations of different genes involved in the PK and pharmacodynamics of T and AI (95 SNPs) at baseline. SE, concurrent medications and compliance were registered by both the pts on a diary card and the physician. Evaluation was done only on new occurrence or increased grade of symptoms.
Results: This first report focuses on characteristics of the population and the results after the 6 first months of treatment. Between June 2010 and October 2014, 23 centers recruited 2000 pts. 23 were excluded leaving 1977 fully evaluable women; 879 (44%) started with T, 1098 (55%) with AI (554 letrozole (L), 390 anastrozole (A), 154 exemestane (E)). 56% of them had previously received chemotherapy, 96% radiotherapy and 8% trastuzumab.
Main characteristics were well balanced between the 2 classes of drugs; T was given mainly for pre- or perimenopausal pts. Most frequent co-morbidities were hypertension (8% T, 31% AI) and dyslipidemia or diabetes (T 11%, AI 26%). To note, almost 30% of pts described arthralgias at entrance and 37% had hot flashes.
At 6 months, 122 pts (6%; 43 T, 79 AI) had stopped treatment mainly for toxicity (11 T; 12 AI), progression or death (7 T; 4 IA), personal reasons (15 T; 37AI); 4 asked for changing T and 52 AI (equally for the 3 drugs). All these events were significantly more frequent for AI pts (p=0.042) and with E within the AI class (p<0.001).
Main changes in onset or increased intensity of symptoms concerned hot flushes with all drugs (30%), asthenia (20%), insomnia (20%), weight gain (17%), arthralgias (15% for T, 30% for AI), thrombotic events (24 of which 11 with T). 3 grade3 SAE HT-related were reported.
Biological data are reported in 2 other abst. (M. White-Koning. abst.#850248, F. Thomas, abst.#851525).
Conclusions: These preliminary data on the first 6-months exposure to HT on adjuvant setting in the real-life confirm early rates of withdraws and toxicities. Longer follow-up and subsequent PK analysis should help to understand persistent side-effects and reasons for non-compliance to adjuvant HT.
Citation Format: Roché H, Venat-Bouvet L, Debled M, Jacot W, Suc E, Dalenc F, Molnar-Stanciu D, Dohollou N, Franck D, Ferrer C, Laharie-Mineur H, Lavau-Denes S, Massabeau C, Mauries V, Robert J, Pinguet F, Marquet P, Evrard A, Chatelut E, Filleron T. First 6-month report of the longitudinal PHACS study (Pharmacology and Hormonotherapy (HT) for Adjuvant breast Cancer (BC) Study, NCT01127295) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-12-10.
Collapse
Affiliation(s)
- H Roché
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - L Venat-Bouvet
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - M Debled
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - W Jacot
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - E Suc
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - F Dalenc
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - D Molnar-Stanciu
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - N Dohollou
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - D Franck
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - C Ferrer
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - H Laharie-Mineur
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - S Lavau-Denes
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - C Massabeau
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - V Mauries
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - J Robert
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - F Pinguet
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - P Marquet
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - A Evrard
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - E Chatelut
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| | - T Filleron
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Cedex 9, France, Metropolitan; CHU Limoges, Limoges, France, Metropolitan; Institut Bergonié, Bordeaux, France, Metropolitan; Institut de Cancérologie de Montpellier, Montpellier, France, Metropolitan; Clinique St Jean du Languedoc, Toulouse, France, Metropolitan; Centre Hospitalier, Brive, France, Metropolitan; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, Metropolitan; Clinique Pasteur, Toulouse, France, Metropolitan; CHU Carémeau, Nîmes, France, Metropolitan; Clinique Tivoli, Bordeaux, France, Metropolitan; Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France, Metropolitan
| |
Collapse
|
6
|
Thomas F, Marquet P, Pinguet F, White-Koning M, Robert J, Tafzi N, Solassol I, Despax R, Levasseur N, Ellis S, Massoubre A, Mbatchi L, Le Morvan V, Roché H, Chatelut E, Evrard A. Abstract P3-12-07: Pharmacogenetic determinants of aromatase inhibitors pharmacokinetics and side effects: 6-month results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-12-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Supported by a PHRC grant (#09-18-005)
Background: Recent literature has suggested that germline genetic variants of drug-metabolizing enzymes or CYP19A1 (coding for aromatase) may be involved in the systemic aromatase inhibitors (AI) concentrations or the occurrence of side effects (Hertz et al. Pharmacogenomics 2017). A prospective multicentre 3-year follow-up study was carried out to investigate the relationships between pharmacogenetics (PG), pharmacokinetics (PK) and toxicity in breast cancer patients treated with adjuvant AI (n=1098) or tamoxifen (n=879). The clinical results and the tamoxifen PG/PK analyses are described elsewhere (abstracts #851544 and #850248).
Methods: SNP genotyping of 95 SNPs was performed on the Biomark (Fluidigm) with Taqman assays and was available for 373, 515 and 151 patients treated with anastrozole (ANA), letrozole (LETRO) and exemestane (EXE) respectively. CYP2A6 metaboliser status (MS) (poor, intermediate or normal) was determined based on alleles function (*1, *9, *2) and number of CYP2A6 copies. Trough plasma concentrations of each drug were determined 6 months after the start of the study by UPLC-MS/MS and were available for 342, 463 and 130 patients of the ANA, LETRO and EXE arms. Patients with AI concentrations below the limit of quantification were excluded for non-compliance (9 patients for ANA, 8 patients for LETRO and 7 patients for EXE). Toxicity was measured as a binary outcome (occurrence or worsening of hot flushes, fatigue, pain, arthralgia, vaginal dryness). All genetic associations were adjusted for multiple testing.
Results: ANA concentration was significantly higher in patients experiencing pain (p=0.025) and was associated with rs28365063 (UGT2B7 g.372A>G).
LETRO concentrations were strongly associated with CYP2A6 metabolizer status (p=0.0001) but did not differ in patients with or without toxicity.
In the EXE arm, patients with hot flushes or arthralgia had a significantly lower level of exemestane (p= 0.0002 and p=0.023 respectively) but since the metabolism of EXE leads to active 17-hydroexemestane, we can hypothesize that the lower EXE concentration is an indirect reflection of the metabolite formation. A SNP (rs2307424) in NR1I3 gene (coding for the constitutive androstane receptor CAR) was associated with EXE concentrations. CAR has been shown to regulate CYP2B6, which is involved in the formation of 6-hydroxy-methyl-exemestane (inactive metabolite).
Regarding the relationships between PG and toxicity, in the ANA arm, 3 SNPs of CYP19A1 gene tended to be associated with hot flushes worsening (rs934635) and arthralgia (rs10046 and rs2304463) but did not remain significant after multiple tests correction. In the EXE arm, several SNPs in NR1I3 gene were associated with fatigue.
In the LETRO arm, patients with a poor CYP2A6 MS had a higher risk of experiencing depression.
Conclusions: Our study confirms the predominant role of CYP2A6 in LETRO PK. To our knowledge, this is the first study to report on the role of UGT2B7 rs28365063 in ANA and NR1I3 in EXE PK and side effects. These relationships need to be re-evaluated with the drug concentrations obtained during the 3-year follow-up.
Citation Format: Thomas F, Marquet P, Pinguet F, White-Koning M, Robert J, Tafzi N, Solassol I, Despax R, Levasseur N, Ellis S, Massoubre A, Mbatchi L, Le Morvan V, Roché H, Chatelut E, Evrard A. Pharmacogenetic determinants of aromatase inhibitors pharmacokinetics and side effects: 6-month results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-12-07.
Collapse
Affiliation(s)
- F Thomas
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - P Marquet
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - F Pinguet
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - M White-Koning
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - J Robert
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - N Tafzi
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - I Solassol
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - R Despax
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - N Levasseur
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - S Ellis
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - A Massoubre
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - L Mbatchi
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - V Le Morvan
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - H Roché
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - E Chatelut
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| | - A Evrard
- Institut Claudius Regaud, IUCT-O, Toulouse, France; CRCT, Inserm, Univ Toulouse, Toulouse, France; CHU Limoges, Limoges, France; ICRM, Montpellier, France; Institut Bergonié, Bordeaux, France; Clinique Pasteur, Toulouse, France; CH Cahors, Cahors, France; Centre Catalan d'Oncologie, Perpignan, France; CHU Carémeaux, Nîmes, France
| |
Collapse
|
7
|
Occhipinti S, Petit-Jean E, Pinguet F, Beaupin C, Daouphars M, Parent D, Donamaria C, Bertrand C, Divanon F, Benard-Thiery I, Chevrier R. Implication du pharmacien dans l’accompagnement des patients sous anticancéreux oraux : état des lieux dans les centres de lutte contre le cancer (CLCC). Bull Cancer 2017; 104:727-734. [DOI: 10.1016/j.bulcan.2017.06.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Revised: 05/07/2017] [Accepted: 06/13/2017] [Indexed: 11/16/2022]
|
8
|
Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS One 2017; 12:e0175998. [PMID: 28481884 PMCID: PMC5421769 DOI: 10.1371/journal.pone.0175998] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Accepted: 04/04/2017] [Indexed: 12/29/2022] Open
Abstract
Background Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The goal of this prospective observational study was to perform exhaustive exome DPYD sequencing and to examine relationships between DPYD variants and toxicity in advanced breast cancer patients receiving capecitabine. Methods Two-hundred forty-three patients were analysed (88.5% capecitabine monotherapy). Grade 3 and grade 4 capecitabine-related digestive and/or neurologic and/or hemato-toxicities were observed in 10.3% and 2.1% of patients, respectively. DPYD exome, along with flanking intronic regions 3’UTR and 5’UTR, were sequenced on MiSeq Illumina. DPD phenotype was assessed by pre-treatment plasma uracil (U) and dihydrouracil (UH2) measurement. Results Among the 48 SNPs identified, 19 were located in coding regions, including 3 novel variations, each observed in a single patient (among which, F100L and A26T, both pathogenic in silico). Combined analysis of deleterious variants *2A, I560S (*13) and D949V showed significant association with grade 3–4 toxicity (sensitivity 16.7%, positive predictive value (PPV) 71.4%, relative risk (RR) 6.7, p<0.001) but not with grade 4 toxicity. Considering additional deleterious coding variants D342G, S492L, R592W and F100L increased the sensitivity to 26.7% for grade 3–4 toxicity (PPV 72.7%, RR 7.6, p<0.001), and was significantly associated with grade 4 toxicity (sensitivity 60%, PPV 27.3%, RR 31.4, p = 0.001), suggesting the clinical relevance of extended targeted DPYD genotyping. As compared to extended genotype, combining genotyping (7 variants) and phenotyping (U>16 ng/ml) did not substantially increase the sensitivity, while impairing PPV and RR. Conclusions Exploring an extended set of deleterious DPYD variants improves the performance of DPYD genotyping for predicting both grade 3–4 and grade 4 toxicities (digestive and/or neurologic and/or hematotoxicities) related to capecitabine, as compared to conventional genotyping restricted to consensual variants *2A, *13 and D949V.
Collapse
Affiliation(s)
| | | | - Christophe Beroud
- Aix-Marseille University, INSERM UMR S910, GMGF, Marseille, France
- APHM Hôpital Timone, Laboratoire de Génétique Moléculaire, Marseille, France
| | - Litaty Mbatchi
- Faculté de Pharmacie de Montpellier, Montpellier, France
| | - André van Kuilenburg
- Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam,The Netherlands
| | | | - Fabienne Thomas
- Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France
| | - Etienne Chatelut
- Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France
| | - Jean-Louis Merlin
- Institut de Cancérologie de Lorraine, UMR CNRS 7039 CRAN, Université de Lorraine, Nancy, France
| | | | | | - Judith Meijer
- Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam,The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | - Henri Roché
- Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France
| | | | | | | | | | | | | | - David Salgado
- Aix-Marseille University, INSERM UMR S910, GMGF, Marseille, France
| | | | | |
Collapse
|
9
|
Poujol S, Pinguet F, Bressole F, Boustta M, Vert M. Molecular Microencapsulation: Paclitaxel Formations in Aqueous Medium Using Hydrophobized Poly(L-Lysine Citramide Imide). J BIOACT COMPAT POL 2016. [DOI: 10.1177/088391150001500201] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Hydrophobized polyelectrolytes are able to aggregate in aqueous media and to form lipophilic microdomains which are much more stable than micelles made of amphiphilic diblock copolymers. Solubilization of paclitaxel in water by molecular encapsulation was attempted in the hydrophobic pockets present in the aggregates of hydrophobized poly(l-lysine citramide imide) polymers, PLCAixRy, where x = percentage in imide groups and y = percentage in alkyl substituents per lysine citramide repeat unit. A comparison was made of the physical entrapment and the solubilization of paclitaxel in PLCAi27C1234, PLCAC1275, PLCAi13C730, PLCAC12100 aggregates and in the usual allergic Cremophor® present in the Taxol® commercial formulation. PLCAixRy polymers solubilized paclitaxel in the selected aqueous medium proportionally to the polymer concentration. For comparable amounts in weight, the polymers were two to six times less efficient than Cremophor® in terms of equivalent mass of solubilizing species. A comparison between PLCAi13C730 and PLCAixC12y polymers suggested that dodecyl hydrophobizing groups were more efficient than heptyl ones in promoting the physical entrapment of paclitaxel. The antitumoral activity of the polymer-solubilized paclitaxel was tested in vitro against an ovarian carcinoma cell line (A2780). The C12 systems showed cytotoxicity, the IC50 values were statistically comparable in the 6.5-10.5 μg/L range. However, the amounts of drug incorporated in the polymer aggregates at the tested concentrations were still too low for clinical use. Improvements are expected from PLCA polymers with longer alkyl chains, greater hydrophobicity and higher concentrations.
Collapse
Affiliation(s)
- S. Poujol
- Department of Pharmacy and Oncopharmacology, Cancer Institute C.R.L.C., Val d'Aurelle, 34298 Montpellier Cedex 5, France
| | - F. Pinguet
- Department of Pharmacy and Oncopharmacology, Cancer Institute C.R.L.C., Val d'Aurelle, 34298 Montpellier Cedex 5, France
| | - F. Bressole
- Department of Pharmacy and Oncopharmacology, Cancer Institute C.R.L.C., Val d'Aurelle, 34298 Montpellier Cedex 5, France
| | - M. Boustta
- CRBA-URA CNRS 1465, Faculty of Pharmacy, University Montpellier I, 34060 Montpellier Cedex 2, France
| | - M. Vert
- CRBA-URA CNRS 1465, Faculty of Pharmacy, University Montpellier I, 34060 Montpellier Cedex 2, France
| |
Collapse
|
10
|
Pinguet F, Poujol S, Martel P, Roch I, Bressolle F. Economic evaluation of 4% albumin solution, gelatine, and hydroxyethylamidon for plasma volume expansion in cancer patients. J Oncol Pharm Pract 2016. [DOI: 10.1177/107815529600200405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose. Given the potential advantages of the use of hydroxyethylamidon, the purpose of this cost analysis was to examine the economic consequences of the use of such derivatives compared to albumin and gelatine for fluid resuscitation in patients with various types of cancer. Methods. We report on the economic evalua tion conducted at the Montpellier Anticancer Center between July 1989 and December 1995. Patients with various types of cancer were included in the study. About 310 patients were treated each year. Since January 1991, an economic policy was undertaken to reduce the cost of treatment by volume expanders. Results. During the study period, the pharma ceutical price of these drugs, the number of patients, and the number of days of hospitalization remained relatively stable. From 1991 to 1995 of this economic evaluation, we observed a regular decrease in the utilization of fluid expanders. Indeed, 2370 vials were used in 1990 and only 868 in 1995. In 1991, a new plasma volume expander, hydroxyethylamidon, be came commercially available. Consequently, from 1992, we observed a decrease in the use of 4% albumin; then, from 1993, there was a decrease in the use of gelatine. In 1989, the mean cost of each vial was $46; it was $16 in 1995. This decrease is attrib utable to a progressive substitution of 4% albumin, then of gelatine, by hydroxyethylamidon. During the 24 first months of the present study, the total cost of plasma volume expanders was approximately $180,000 (July 1989 to June 1991); it was $164,000 during the following 54 months (July 1991 to Decem ber 1995). Conclusion. The pharmaceutical economic pol icy and the risk of using blood product have contrib uted to a decrease in the total cost of the different drugs used as plasma volume expanders. To date, the savings realized have been ∼$75,000 annually.
Collapse
Affiliation(s)
- Frédéric Pinguet
- Pharmacy-Oncopharmacology Service, Anticancer Center, Montpellier, France
| | - Sylvain Poujol
- Pharmacy-Oncopharmacology Service, Anticancer Center, Montpellier, France
| | - Pascal Martel
- Pharmacy-Oncopharmacology Service, Anticancer Center, Montpellier, France
| | - Isabelle Roch
- Pharmacy-Oncopharmacology Service, Anticancer Center, Montpellier, France
| | - Francoise Bressolle
- Pharmacy-Oncopharmacology Service, Anticancer Center, Montpellier, France, Faculty of Pharmacy, University Montpellier I, Montpellier, France
| |
Collapse
|
11
|
Dell'Ova M, De Maio E, Guiu S, Roca L, Dalenc F, Durigova A, Pinguet F, Bekhtari K, Jacot W, Pouderoux S. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study. BMC Cancer 2015; 15:659. [PMID: 26449988 PMCID: PMC4599752 DOI: 10.1186/s12885-015-1673-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2015] [Accepted: 10/01/2015] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. METHODS Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were included in the study. Clinical and biological assessment of toxicity was performed at each visit. Tumour response was assessed every 3 cycles of treatment. A database was created to collect clinical, pathological and treatment data. RESULTS Two hundred and fifty-eight patients were included in the study. Median age was 59 years old. Tumours were Hormone Receptor (HR)-positive (73.3 %) HER2-positive (10.2 %), and triple negative (TN, 22.5 %). 86.4 % of the patients presented with visceral metastases, mainly in the liver (67.4 %). Median previous metastatic chemotherapies number was 4 [1-9]. Previous treatments included anthracyclines and/or taxanes (100 %) and capecitabine (90.7 %). Median number of EM cycles was 5 [1-19]. The relative dose intensity was 0.917. At the time of analysis (median follow-up of 13.9 months), 42.3 % of the patients were still alive. The objective response rate was 25.2 % (95 %CI: 20-31) with a 36.1 % clinical benefit rate (CBR). Median time to progression (TTP) and overall survival were 3.97 (95 %CI: 3.25-4.3) and 11.2 (95 %CI: 9.3-12.1) months, respectively. One- and 2-year survival rates were 45.5 and 8.5 %, respectively. In multivariate analysis, HER2 positivity (HR = 0.29), the presence of lung metastases (HR = 2.49) and primary taxanes resistance (HR = 2.36) were the only three independent CBR predictive factors, while HR positivity (HR = 0.67), the presence of lung metastases (HR = 1.52) and primary taxanes resistance (HR = 1.50) were the only three TTP independent prognostic factors. Treatment was globally well tolerated. Most common grade 3-4 toxicities were neutropenia (20.9 %), peripheral neuropathy (3.9 %), anaemia (1.6 %), liver dysfunction (0.8 %) and thrombocytopenia (0.4 %). Thirteen patients (5 %) developed febrile neutropenia. CONCLUSION EM is an effective new option in heavily pretreated MBC, with a favourable efficacy/safety ratio in a clinical practice setting. Our results comfort the use of this new molecule and pledge for the evaluation of EM-trastuzumab combination in this setting. Tumour biology, primary taxanes sensitivity and metastatic sites could represent useful predictive and prognostic factors.
Collapse
Affiliation(s)
- Mélodie Dell'Ova
- Département de Pharmacie Clinique, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Eléonora De Maio
- Medical Oncology Department, Institut Claudius Regaud, IUCT- Oncopole, Toulouse, France.
| | - Séverine Guiu
- Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France.
- Breast Center (CePO), University Hospital CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
| | - Lise Roca
- Département de Biostatistiques, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Florence Dalenc
- Medical Oncology Department, Institut Claudius Regaud, IUCT- Oncopole, Toulouse, France.
| | - Anna Durigova
- Département d'Oncologie Médicale, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
- Medical Oncology Department, University Hospital of Geneva, Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland.
| | - Frédéric Pinguet
- Département de Pharmacie Clinique, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Khedidja Bekhtari
- Département de Pharmacie Clinique, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - William Jacot
- Département d'Oncologie Médicale, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Stéphane Pouderoux
- Département d'Oncologie Médicale, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| |
Collapse
|
12
|
Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D, Ollivier C, Bardin C, Lemare F, Daouphars M, Pinguet F, Latour JF, Vigneron J, Tilleul P. [Study impacto: Descriptive analyzis of pharmacist's clinical practice in onco-hematology]. Ann Pharm Fr 2015; 73:223-8. [PMID: 25934530 DOI: 10.1016/j.pharma.2014.10.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Revised: 10/10/2014] [Accepted: 10/10/2014] [Indexed: 11/29/2022]
Abstract
Pharmaceutical analyses of chemotherapy prescriptions by hospital pharmacists are activities codified by regulation and rules (bon usage). The involvement of the pharmacists in clinical pharmacy activities in the oncology setting is not clearly identified, justifying the development of a mapping of these activities from a questionnaire addressed to the professionals. One hundred and seven centers have participated to this study at the national level (overall participation rate of 32.4%). More than 95% of them used a computerized ordering system and three quarter of them submit the introduction of new compounds to an analysis by the drug therapeutic committee. Prescription analysis allowed detecting around 2% of errors from the current prescription. Clinical pharmacist participates to tumor boards of onco-hematology (RCP) at a level of 46% for senior pharmacist and 42% for junior pharmacist. This involvement in the RCP allowed anticipating protocol's modification and temporary used authorization. Ninety-two percent of the senior pharmacists estimate that they highlight the risk of no reimbursement for prescription out of the guideline during RCP, resulting to a modification of the prescription for 40% of them. This level of intervention is lower with respectively 64% and 10% for the juniors. This study underlines the expert value of the clinical pharmacist dedicated to oncology setting in pre and post analysis prescriptions. It could be targeted by a prospective analysis of both clinical and pharmacoeconomics impact of these interventions.
Collapse
Affiliation(s)
- R Le Guen
- Pharmacie Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France.
| | - I Madelaine
- Pharmacie St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J-F Tournamille
- Pharmacie Bretonneau, 2, boulevard Tonnelle, 37044 Tours, France
| | - A Bellanger
- Pharmacie Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France
| | - A Astier
- Pharmacie Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny 94100 Créteil, France
| | - D Braguer
- Université Aix-Marseille II, UMR 911-CRO2 faculté de médecine, 27, boulevard Jean-Moulin 13385 Marseille, France
| | - C Ollivier
- Pharmacie, CHU Caen, avenue de la Côte-de-Nacre, 14033 Caen, France
| | - C Bardin
- Pharmacie Cochin, 27, rue du Faubourg-St-Jacques, 75014 Paris, France
| | - F Lemare
- Pharmacie IGR, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Faculté de pharmacie, université Paris Descartes, 4, rue de l'Observatoire, 75006, Paris, France
| | - M Daouphars
- Pharmacie, CRLC Henri-Becquerel, rue d'Amiens, 76038 Rouen, France
| | - F Pinguet
- Pharmacie, CRLC Val-d'Aurelle-Parc Euromédecine 208, rue des Apothicaires, 34298 Montpellier, France
| | - J-F Latour
- Pharmacie, centre Léon-Bérard, 28, rue Laennec, 69373 Lyon, France
| | - J Vigneron
- Pharmacie, CHU Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France
| | - P Tilleul
- Pharmacie Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France; Faculté de pharmacie, université Paris Descartes, 4, rue de l'Observatoire, 75006, Paris, France
| |
Collapse
|
13
|
Dell'Ova M, De Maio E, Guiu S, Roca L, Dalenc F, Jacot W, Durigova A, Pinguet F, Bekhtari K, Pouderoux S. Eribex: a Retrospective, International, Multicenter Study on the Efficacy and Safety of Eribuline Mesylate in Metastatic Breast Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Milano G, Ferrero JM, Thomas F, Bobin-Dubigeon C, Merlin JL, Pinguet F, Ferrand C, Boyer JC, Romieu G, Bachelot T, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roche H, Bonneterre J, De Clercq B, Etienne-Grimaldi MC. Abstract P3-15-04: A French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-15-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Health Authorities point out that DPD deficiency confers a significant risk of major toxicity for patients receiving capecitabine. Identification of at-risk patients is thus of major concern. This multicentric prospective study of the French GPCO group (Groupe de Pharmacologie Clinique Oncologique, Unicancer) evaluated the sensitivity, specificity and predictive values of DPD phenotyping and genotyping to predict severe cap-related toxixity in metastatic breast cancer patients.
Methods: 303 patients were included between February 2009 and February 2011 (15 institutions). Eighty-eight% received capecitabine as monotherapy, 28% were treated as first line (mean dose at 1st cycle 1957 mg/m2/d). Pre-treatment uracil (U, physiological DPD substrate) plasma concentration was measured in 286 patients (HPLC assay). DPD genotyping (IVS14+1G>A, 2846A>T, 1679T>G, 464T>A) was performed on 281 patients. Severe toxicity (G3-4 CTCAE v3 criteria) was measured over cycles 1-2.
Results: Grade 3-4 toxicity (diarrhea, vomiting, hematoxicity, hand-foot syndrome) has been observed in 19.6% of patients (one toxic death). A marked trend for higher U concentrations has been noted in patients developing severe toxicity vs those who didn't (median 12.7 ng/ml (Q1-Q3 9-17) vs median 10.2 ng/ml (range 8-13), respectively, p = 0.014). However, ROC curve has showed that this difference was too small for use as a reliable toxicity predictor. The patient with toxic death had an elevated U concentration at 17 ng/ml. Among the 7 patients with a DPD mutation (3 pts IVS14+1, 3 pts 2846A>T, one 1679T>G, all heterozygous), 5 developed severe toxicity (including the toxic death, 2846A>T), one did not, and the last one was not documented. Relative risk for developing severe toxicity was 4.60 in mutated patients vs wild-type patients (95%CI 2.95-7.16, p = 0.001); positive and negative predictive values were 83.3% and 81.9%, respectively; specificity was 99.5% and sensitivity was 9.8%.
Conclusions: Breast cancer patients harbouring a DPD variant allele are at risk to develop severe, up to lethal, capecitabine-related toxicity. Pre-treatment U measurement remains to be more firmly established as a reliable predictor of capecitabine toxicity. These observations are of major interest for breast cancer patients candidate for capecitabine therapy.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-15-04.
Collapse
Affiliation(s)
- G Milano
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - J-M Ferrero
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - F Thomas
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - C Bobin-Dubigeon
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - J-L Merlin
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - F Pinguet
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - C Ferrand
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - J-C Boyer
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - G Romieu
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - T Bachelot
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - X Pivot
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - V Dieras
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - R Largillier
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - M Mousseau
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - A Goncalves
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - H Roche
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - J Bonneterre
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - B De Clercq
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| | - M-C Etienne-Grimaldi
- Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
15
|
Duffour J, Roca L, Bressolle F, Abderrahim A, Poujol S, Pinguet F, Ychou M. Clinical Impact of Intensified 5-Fluorouracil-Based Chemotherapy Using a Prospective Pharmacokinetically-Guided Dosing Approach: Comparative Study in Elderly and Non-Elderly Patients with Metastatic Colorectal Cancer. J Chemother 2013; 22:179-85. [DOI: 10.1179/joc.2010.22.3.179] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
16
|
Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, Trittler R, Daouphars M, Paul M, Trojniak M, Pinguet F. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference: Table 1. Eur J Hosp Pharm 2012. [DOI: 10.1136/ejhpharm-2012-000112] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
17
|
Poujol S, Bressolle F, Solassol I, Pinguet F. Stability of ready-to-use temsirolimus infusion solution (100mg/L) in polypropylene containers under different storage conditions. Annales Pharmaceutiques Françaises 2012; 70:155-62. [DOI: 10.1016/j.pharma.2012.03.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2012] [Revised: 03/16/2012] [Accepted: 03/21/2012] [Indexed: 10/28/2022]
|
18
|
Mazard T, Ychou M, Thezenas S, Poujol S, Pinguet F, Thirion A, Bleuse JP, Portales F, Samalin E, Assenat E. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX. Cancer Chemother Pharmacol 2011; 69:807-14. [PMID: 22037922 DOI: 10.1007/s00280-011-1764-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2011] [Accepted: 10/12/2011] [Indexed: 12/27/2022]
Abstract
BACKGROUND Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors. PATIENTS AND METHODS In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively. RESULTS In XELIRI, a total of 136 chemotherapy cycles were administered with a median number of 8 cycles per patient (2-16). Main dose-limiting toxicities (DLT) were grade 3-4 neutropenia, with one toxicity-related death. Maximum tolerated dose (MTD) for capecitabine combined with 180 mg/m(2) of irinotecan was 3,500 mg/m(2)/day. In XELIRINOX, capecitabine starting dose was 2,500 mg/m(2)/day. Fifty-eight chemotherapy cycles were administered with a median of 4 cycles per patient (1-16). DLT included 3 grade 4 neutropenia, associated with 1 grade 3 diarrhea, and 1 grade 4 pneumopathy leading to patient death. MTD for capecitabine with 180 mg/m(2) of irinotecan and 85 mg/m(2) of oxaliplatin was 3,000 mg/m(2)/day. The recommended doses for capecitabine were 3,000 and 2,500 mg/m(2)/day D1-D7 in combination with 180 mg/m(2) of irinotecan in XELIRI, plus 85 mg/m(2) of oxaliplatin in XELIRINOX (D1 = D14), respectively. CONCLUSION XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in metastatic colorectal cancer patients.
Collapse
Affiliation(s)
- T Mazard
- Département d'Oncologie Médicale, CHU Saint Eloi, Montpellier, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, Trittler R, Pinguet F, Daouphars M, Paul M, Trojniak M. 1307 POSTER European Consensus Conference on the Practical Stability of Anticancer Drugs. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70881-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, Trittler R, Daouphars M, Paul M, Trojniak M, Pinguet F. Guidelines for the practical stability studies of anticancer drugs: A European consensus conference. Annales Pharmaceutiques Françaises 2011; 69:221-31. [DOI: 10.1016/j.pharma.2011.07.002] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Accepted: 07/07/2011] [Indexed: 10/17/2022]
|
21
|
Švobaitė R, Solassol I, Pinguet F, Mazard T, Ivanauskas L, Ychou M, Bressolle FMM. A LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY METHOD FOR THE SIMULTANEOUS DETERMINATION OF CAPECITABINE, 5′-DEOXY-5-FLUOROCYTIDINE, 5′-DEOXY-5-FLUOROURIDINE, 5-FLUOROURACIL, AND 5-FLUORODIHYDROURACIL IN HUMAN PLASMA. J LIQ CHROMATOGR R T 2010. [DOI: 10.1080/10826076.2010.503842] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- R. Švobaitė
- a Pharmacokinetic Laboratory , Faculty of Pharmacy, University Montpellier I , Montpellier, France
- b Department of Analytical and Toxicological Chemistry , Kaunas University of Medicine , Kaunas, Lithuania
- c Oncopharmacology Department , Pharmacy Service, Val d'Aurelle Anticancer Centre , Montpellier, France
| | - I. Solassol
- c Oncopharmacology Department , Pharmacy Service, Val d'Aurelle Anticancer Centre , Montpellier, France
| | - F. Pinguet
- c Oncopharmacology Department , Pharmacy Service, Val d'Aurelle Anticancer Centre , Montpellier, France
| | - T. Mazard
- d Department of Medical Oncology , Val d'Aurelle Anticancer Centre , Montpellier, France
| | - L. Ivanauskas
- b Department of Analytical and Toxicological Chemistry , Kaunas University of Medicine , Kaunas, Lithuania
| | - M. Ychou
- d Department of Medical Oncology , Val d'Aurelle Anticancer Centre , Montpellier, France
| | - F. M. M. Bressolle
- a Pharmacokinetic Laboratory , Faculty of Pharmacy, University Montpellier I , Montpellier, France
- c Oncopharmacology Department , Pharmacy Service, Val d'Aurelle Anticancer Centre , Montpellier, France
| |
Collapse
|
22
|
Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol 2010; 28:4568-74. [PMID: 20855828 DOI: 10.1200/jco.2010.29.3597] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Area under the curve (AUC) dosing is routinely carried out for carboplatin, but the chosen target AUC values remain largely empirical. This multicenter pharmacokinetic-pharmacodynamic (PK-PD) study was performed to determine the covariates involved in the interindividual variability of carboplatin hematotoxicity that should be considered when choosing individual target AUCs. PATIENTS AND METHODS Three hundred eighty-three patients received carboplatin as part of established regimens. A semi-physiologic population PK-PD model was applied to describe separately the time course of absolute neutrophil and platelet counts using NONMEM software. The plasma ultrafiltrable carboplatin concentration (C(Carbo)) was assumed to inhibit the proliferation of blood cell precursors through a linear model: drug effect = slope × C(Carbo). The slope corresponds to the patients' sensitivity to carboplatin hematotoxicity. The relationships between the patients' sensitivity to the neutropenic or thrombopenic effects of carboplatin and various covariates, including associated chemotherapies, demographic, biologic, and pharmacogenetic data, were studied. RESULTS The sensitivity of carboplatin-induced thrombocytopenia decreased in the case of concomitant paclitaxel chemotherapy (slope decreased by 24%), whereas it increased with coadministration of etoposide and gemcitabine (slope increased by 45% and 133%, respectively). For neutropenia, the sensitivity increased when carboplatin was combined with other cytotoxics (slope increased by 76%). CONCLUSION This study provides useful information to clinicians to better estimate the hematopoietic toxicity of carboplatin and thus choose more rationally carboplatin target AUCs as a function of pretreatment or concomitantly administered chemotherapies. For example, an AUC of 5 mg/mL · min is associated with a risk of grade 3 or 4 thrombocytopenia of 2% in combination with paclitaxel versus 38% with gemcitabine in a non-pretreated patient.
Collapse
Affiliation(s)
- Antonin Schmitt
- Institut Claudius-Regaud and EA3035 University of Toulouse, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Khier S, Gattacceca F, El Messaoudi S, Lafaille F, Deleuze-Masquéfa C, Bompart J, Cooper JF, Solassol I, Pinguet F, Bonnet PA, Bressolle FMM. Metabolism and Pharmacokinetics of EAPB0203 and EAPB0503, Two Imidazoquinoxaline Compounds Previously Shown to Have Antitumoral Activity on Melanoma and T-Lymphomas. Drug Metab Dispos 2010; 38:1836-47. [DOI: 10.1124/dmd.110.034579] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
|
24
|
Khier S, Deleuze-Masquéfa C, Moarbess G, Gattacceca F, Margout D, Solassol I, Cooper JF, Pinguet F, Bonnet PA, Bressolle FM. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. Eur J Pharm Sci 2010; 39:23-9. [DOI: 10.1016/j.ejps.2009.10.006] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2009] [Revised: 09/30/2009] [Accepted: 10/13/2009] [Indexed: 10/20/2022]
|
25
|
Deleuze-Masquefa C, Moarbess G, Khier S, David N, Gayraud-Paniagua S, Bressolle F, Pinguet F, Bonnet PA. New imidazo[1,2-a]quinoxaline derivatives: Synthesis and in vitro activity against human melanoma. Eur J Med Chem 2009; 44:3406-11. [DOI: 10.1016/j.ejmech.2009.02.007] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2008] [Revised: 01/26/2009] [Accepted: 02/12/2009] [Indexed: 11/24/2022]
|
26
|
Khier S, Moarbess G, Deleuze-Masquefa C, Solassol I, Margout D, Pinguet F, Bonnet PA, Bressolle FMM. Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS. J Sep Sci 2009; 32:1363-73. [PMID: 19399864 DOI: 10.1002/jssc.200800668] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Since several years, our group developed quinoxalinic compounds. Among the synthesized compounds, in the imidazo[1,2-a]quinoxaline series, EAPB0203 has shown interesting activities both on melanoma and lymphoma. The structure of EAPB0203 has been modulated and a new compound, EAPB0503, exhibits an in vitro cytotoxic activity on melanoma cancer cell line 7-9 times higher than EAPB0203. We validated an LC/ESI-MS method to simultaneously quantify EAPB0503 and its metabolite EAPB0603 in human and rat plasma. Chromatography was performed on a C8 Zorbax eclipse XDB column with a mobile phase consisting of acetronitrile and formate buffer gradient elution. LC-MS data were acquired in SIM mode at m/z 305, 291, and 303 for EAPB0503, EAPB0603, and the internal standard, respectively. The drug/internal standard peak area ratios were linked via quadratic relationships to concentrations (low range: 5-300 microg/L, high range: 100-1000 microg/L). The method is precise (precision, < or = 14%) and accurate (recovery, 92-113%). Mean extraction efficiencies, > 72% for each analyte, were obtained. The lower LOQs were 5 microg/L. This highly specific and sensitive method was successfully used to investigate plasma concentrations of EAPB0503 and EAPB0603 in a pharmacokinetic study carried out in rat and would also be useful in clinical trials at a later stage.
Collapse
Affiliation(s)
- Sonia Khier
- Clinical Pharmacokinetic Laboratory, EA4215, Faculty of Pharmacy, University Montpellier I, France
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Charasson V, Hillaire-Buys D, Solassol I, Laurand-Quancard A, Pinguet F, Le Morvan V, Robert J. Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model. Eur J Cancer 2009; 45:2391-401. [PMID: 19501504 DOI: 10.1016/j.ejca.2009.05.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2009] [Revised: 05/07/2009] [Accepted: 05/08/2009] [Indexed: 12/27/2022]
Abstract
Folate, a vitamin of the B group involved in one-carbon group metabolism, plays an important role in DNA synthesis and methylation. Several polymorphisms in the genes involved in folate uptake and biotransformations have been shown to be associated to the risk of cancer and to anticancer drug response. We studied common polymorphisms in MTHFR (N(5,10)-methylene-tetrahydrofolate reductase), MTHFD1 (N(5,10)-methylene-tetrahydrofolate dehydrogenase), MTR (methionine synthetase) and SLC19A1 (reduced folate carrier) in the panel of 60 human tumour cell lines established by the NCI for anticancer drug screening and we tentatively associated these polymorphisms with gene expression and drug cytotoxicity as extracted from the public database of the Developmental Therapeutic Programme. We observed a consistent and highly significant association between the presence of the variant C allele of the A>C1298 polymorphism of MTHFR and the sensitivity to many anticancer drugs belonging to the classes of antifolates, antimetabolites, alkylating agents and, to a lesser extent, topoisomerase inhibitors. In contrast, the T variant allele of the C>T677 variation of MTHFR was rather associated to lower sensitivity of the cell lines towards anticancer drugs (alkylating agents, antifolates and antimetabolites) but with much lower effects than the A>C1298 variation. The polymorphisms of the other genes studied were not associated with differences in anticancer drug sensitivity, but the expression of the SLC19A1 gene was significantly correlated with the sensitivity to several drugs (antifolates, thiopurines, nitrosoureas, and DACH-platinum drugs). We concluded that the NCI-60 panel may constitute a good starting point for implementing clinical studies aimed at discovering and validating predictive genetic markers of drug efficacy and/or toxicity.
Collapse
Affiliation(s)
- Virginie Charasson
- Laboratoire de Pharmacologie et Toxicologie Clinique, Hôpital Lapeyronie et Université de Montpellier 1, 34295 Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
28
|
Chatelut E, Schmitt A, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi M, Boisdron-Celle M, Pinguet F, Floquet A, Billaud E, Le Guellec C. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2527 Background: It has recently been shown that it is possible to improve the prediction of carboplatin clearance by adding plasma cystatin C level (cysC), an endogenous marker of glomerular filtration rate, to the other patient characteristics routinely used for carboplatin individual dosing, namely serum creatinine (Scr), body weight (BW), age, and sex. This multi-center pharmacokinetic study was performed to evaluate prospectively the benefit of using cysC for carboplatin individual dosing. Methods: The 357 patients included in the study were receiving carboplatin as part of established protocols. A population pharmacokinetic analysis was performed using the NONMEM program. Seven covariates were studied: Scr, cysC, age, sex, BW, ideal body weight, and lean body mass. Results: The best covariate equation was: carboplatin clearance (mL/min) = 105. (Scr/75)-0.433. (cysC/1.00)-0.290 . (BW/65)+0.547 . (age/56)-0.351 . 0.855sex, with Scr in μmol/L, cysC in mg/L, BW in kg, age in years, and sex = 0 for male. Using an alternative weight descriptor (ideal body weight or lean body mass) did not improve the prediction. This final covariate model was validated by bootstrap analysis. The bias (mean percentage error) and imprecision (mean absolute percentage error) were +2% and 15% respectively on the total population, and were of a similar magnitude in each of the three subgroups of patients defined according to their body mass index. Conclusions: For the first time, a unique formula is proposed for carboplatin individual dosing to patients which is shown to be equally valid for underweight, normal weight, and obese patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Chatelut
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - A. Schmitt
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - A. Lansiaux
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - C. Bobin-Dubigeon
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - M. Etienne-Grimaldi
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - M. Boisdron-Celle
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - F. Pinguet
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - A. Floquet
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - E. Billaud
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - C. Le Guellec
- Institut Claudius-Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Saint-Herblain, France; Centre Antoine Lacassagne, Nice, France; Centre Paul Papin, Angers, France; Centre Val d'Aurelle, Montpellier, France; Institut Bergonié, Bordeaux, France; Hôpital Européen Georges Pompidou, Paris, France; Centre Hospitalier Régional Universitaire de Tours, Tours, France
| |
Collapse
|
29
|
Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E. A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients. Clin Cancer Res 2009; 15:3633-9. [DOI: 10.1158/1078-0432.ccr-09-0017] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Moarbess G, Deleuze-Masquefa C, Bonnard V, Gayraud-Paniagua S, Vidal JR, Bressolle F, Pinguet F, Bonnet PA. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg Med Chem 2008; 16:6601-10. [PMID: 18513976 DOI: 10.1016/j.bmc.2008.05.022] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2008] [Revised: 05/02/2008] [Accepted: 05/07/2008] [Indexed: 11/19/2022]
Abstract
Imidazoquinoxaline and pyrazoloquinoxaline derivatives, analogues of imiquimod, were synthesized, and their in vitro cytotoxic and pharmacodynamic activities were evaluated. In vitro cytotoxicity studies were assessed against melanoma (A375, M4Be, RPMI-7591), colon (LS174T), breast (MCF7), and lymphoma (Raji) human cancer cell lines. In vivo studies were carried out in M4Be xenografted athymic mice. EAPB0103, EAPB0201, EAPB0202, and EAPB0203 showed significant in vitro activities against A375 compared to fotemustine and imiquimod used as references. These compounds were 6-110 and 2-45 times more active than fotemustine and imiquimod, respectively. EAPB0203 bearing phenethyl as substituent at position 1 and methylamine at position 4 showed the highest activity. EAPB0203 has also a more potent cytotoxic activity than imiquimod and fotemustine in M4Be and RPMI-7591 and interesting cytotoxic activity in other tumor cell lines tested. In vivo, EAPB0203 treatment schedules caused a significant decrease in tumor size compared to vehicle control and fotemustine treatments.
Collapse
Affiliation(s)
- Georges Moarbess
- Laboratoire de Pharmacochimie et Biomolécules, EA 4215, Faculté de Pharmacie, Université Montpellier I, 15 av. Charles Flahault, BP 14491, 34 093 Montpellier Cedex 5, France
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Delord JP, Dalenc F, Pinguet F, Nguyen L, Lochon I, Poublanc M, Chatelut E, Roche H. A Phase I Dose-Escalating and Pharmacokinetic Study of Docetaxel and Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. Oncology 2008; 72:322-5. [DOI: 10.1159/000113055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2007] [Accepted: 07/27/2007] [Indexed: 11/19/2022]
|
32
|
Culine S, El Demery M, Lamy PJ, Iborra F, Avancès C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007; 178:844-8; discussion 848. [PMID: 17631339 DOI: 10.1016/j.juro.2007.05.044] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2006] [Indexed: 10/23/2022]
Abstract
PURPOSE A link between neuroendocrine cell differentiation and resistance to androgen deprivation has been observed in prostate cancer, suggesting the possible efficacy of specific treatments. We assessed the efficacy and toxicity of a chemotherapy regimen combining docetaxel and cisplatin in men with androgen independent prostatic adenocarcinoma and circulating neuroendocrine markers. MATERIALS AND METHODS A total of 41 patients were treated with a combination of 75 mg/m(2) docetaxel and 75 mg/m(2) cisplatin every 3 weeks for a maximum of 6 cycles. The primary study end point was the neuroendocrine response rate, defined as a decrease in neuron specific enolase and/or chromogranin A to 50% or greater of the supranormal baseline serum value. Median followup was 40 months. RESULTS A median of 6 cycles per patient was delivered. A neuroendocrine response was observed in 13 patients (33%). The median response duration was 4 months (range 2 to 10). The prostate specific antigen response rate was 48%. A clinical benefit was observed in 45% of patients who required analgesics at study entry. The objective response rate was 41% in 29 patients with measurable metastases. Five patients had to stop therapy due to toxicity. The main side effects were cumulative asthenia and sensitive neuropathy. Median survival was 12 months (range 1 to 38). CONCLUSIONS Regarding the disappointing efficacy and significant toxicity observed in this study, the combination of docetaxel and cisplatin cannot be recommended in daily practice. Further studies are necessary to determine whether patients with circulating neuroendocrine markers require specific therapeutic approaches.
Collapse
Affiliation(s)
- Stéphane Culine
- Centre Régional de Lutte Contre le Cancer Val d'Aurelle, Montpellier, France.
| | | | | | | | | | | |
Collapse
|
33
|
Colombo PE, Boustta M, Poujol S, Pinguet F, Rouanet P, Bressolle F, Vert M. Biodistribution of doxorubicin-alkylated poly(l-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Eur J Pharm Sci 2007; 31:43-52. [PMID: 17383164 DOI: 10.1016/j.ejps.2007.02.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2006] [Revised: 02/08/2007] [Accepted: 02/14/2007] [Indexed: 10/23/2022]
Abstract
Peritoneal spread is a common manifestation in ovarian and gastrointestinal cancer. Intraperitoneal (i.p.) chemotherapy after cytoreductive surgery is associated with high systemic or local toxicity. A macromolecular drug delivery system was evaluated with the aim of improving the therapeutic index of i.p. chemotherapy. Peritoneal carcinomatosis was generated in BDIX rats (n=55) by i.p. injection of 2 million DHDK12 cells. Fourteen days later, doxorubicin (DOX) and two DOX-alkylated poly(L-lysine citramide imide) conjugates bearing 9.5% and 20.5% (w/w) chemically bound drug, respectively, were given i.p. to rats at a single 2 mg DOX/kg dose. Free and polymer-bound DOX were assessed in plasma, peritoneal fluid, abdominal tissues and heart, 15 min, 2, 6, 24, 48 and 168 h after injection. According to pharmacokinetic profiles, the peritoneal fluid areas under the concentration versus time curves (AUCs) were 2 and 2.6 times greater for the conjugates (P-DOX20 and P-DOX10, respectively) than for the free drug, respectively. Conjugates crossed the peritoneal barrier slower than the free drug. For the tumor, AUCs were, respectively, 3 and 7 times higher for the conjugates than for free DOX. The elimination half-lives of the conjugates were higher than that calculated for the free drug. Only very small concentrations were detected in peripheral organs and in the heart. In contrast, significant retention and accumulation of the conjugates were found in abdominal organs, particularly in the tumor. There was no sign of macroscopic chemical peritonitis after injection of the polymer-DOX conjugates. In conclusion, the conjugates have higher elimination half-lives than free DOX and were preferentially retained in abdominal organs and in the peritoneal carcinomatosis. This feature is of clinical interest to target tumor deposits.
Collapse
Affiliation(s)
- Pierre-Emmanuel Colombo
- Department of Surgical Oncology, Centre Régional de Lutte Contre le Cancer, 208 Rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 5, France.
| | | | | | | | | | | | | |
Collapse
|
34
|
Solassol I, Bressolle F, Philibert L, Charasson V, Astre C, Pinguet F. Liquid Chromatography‐Electrospray Mass Spectrometry Determination of Imatinib and Its Main Metabolite, N‐Desmethyl‐Imatinib in Human Plasma. J LIQ CHROMATOGR R T 2007. [DOI: 10.1080/10826070600981058] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- I. Solassol
- a Onco‐pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre, parc Euromédecine , Montpellier, France
| | - F. Bressolle
- a Onco‐pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre, parc Euromédecine , Montpellier, France
- b Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy , University Montpellier I , Montpellier, France
| | - L. Philibert
- a Onco‐pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre, parc Euromédecine , Montpellier, France
- b Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy , University Montpellier I , Montpellier, France
| | - V. Charasson
- a Onco‐pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre, parc Euromédecine , Montpellier, France
- c Department of Medical Pharmacology and Toxicology , Lapeyronie Hospital , Montpellier, France
| | - C. Astre
- a Onco‐pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre, parc Euromédecine , Montpellier, France
| | - F. Pinguet
- a Onco‐pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre, parc Euromédecine , Montpellier, France
| |
Collapse
|
35
|
Boucaud M, Pinguet F, Poujol S, Astre C, Bressolle F. SENSITIVE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC FLUORESCENCE DETERMINATION OF TOPOTECAN IN HUMAN PLASMA AND PAROTID SALIVA. J LIQ CHROMATOGR R T 2007. [DOI: 10.1081/jlc-100100495] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- M. Boucaud
- a Centre Régional de Lutte contre le Cancer , Laboratoire d'Onco-Pharmacologie, Montpellier Cedex, 34094, France
| | - F. Pinguet
- a Centre Régional de Lutte contre le Cancer , Laboratoire d'Onco-Pharmacologie, Montpellier Cedex, 34094, France
| | - S. Poujol
- a Centre Régional de Lutte contre le Cancer , Laboratoire d'Onco-Pharmacologie, Montpellier Cedex, 34094, France
| | | | | |
Collapse
|
36
|
Aragon PJ, Yapi AD, Pinguet F, Chezal JM, Teulade JC, Blache Y. Synthesis and Biological Evaluation of Indoloquinolines and Pyridocarbazoles: A New Example of Unexpected Photoreduction Accompanying Photocyclization. Chem Pharm Bull (Tokyo) 2007; 55:1349-55. [PMID: 17827760 DOI: 10.1248/cpb.55.1349] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Indoloquinoline alkaloid cryptolepine and pyridocarbazole alkaloid ellipticine are of great interest because in vitro and in vivo studies revealed their good cytotoxic properties. In order to obtain some biologically active analogs of these compounds, we developed a synthesis based on the photocyclization of tertiary N-substituted enaminones derived from 1,3-cyclohexandione and 3 or 6-aminoquinoline. The angular cyclized compounds thus obtained were tested in vitro on K 562 cells and A 2780 doxorubicin sensitive and resistant cells. All compounds were less effective than doxorubicin in sensitive cells but their activity wasn't decreased by MDR resistance.
Collapse
Affiliation(s)
- Pierre-Jean Aragon
- Laboratoire de Chimie Organique Pharmaceutique, EA 2414, Faculté de Pharmacie, Montpellier, France
| | | | | | | | | | | |
Collapse
|
37
|
Duffour J, Gourgou S, Desseigne F, Debrigode C, Mineur L, Pinguet F, Poujol S, Chalbos P, Bressole F, Ychou M. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemother Pharmacol 2006; 60:383-9. [PMID: 17124595 DOI: 10.1007/s00280-006-0372-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2006] [Accepted: 10/24/2006] [Indexed: 10/23/2022]
Abstract
PURPOSE Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC). This phase II study aimed to assess whether increasing the irinotecan dose in the first line FOLFIRI regimen would benefit mCRC patients. PATIENTS AND METHODS Patients received FOLFIRI every 2 weeks for up to six cycles, comprising a 5-FU/LV regimen combined with irinotecan at 180 mg/m2 (cycle 1), increasing to 220 mg/m2 (cycle 2) and 260 mg/m2 (cycle 3 and subsequent cycles) dependent on toxicity. Efficacy and safety were determined in the intention to treat (ITT) population and in patients able to receive irinotecan at 260 mg/m2 for at least four cycles [high-dose (HD) population]. RESULTS Fifty-four eligible patients were included. Among them, 44 (81.5%) formed the HD population. The ITT objective response rate was 48% (90%CI: 36-60) with 25/26 of the responses in the HD population. The disease control rate was 76% (90%CI: 65-85) and median overall survival was 20.4 months (90%CI: 6.4-27.1). The main grade 3/4 toxicities (ITT/HD populations) were neutropenia (61%/59%), and diarrhoea (18%/11%), respectively. CONCLUSIONS This study confirms the feasibility of increasing the standard dose of the irinotecan component of FOLFIRI to 260 mg/m2, for more than 80% of patients but does not support a clear advantage of this strategy on unselected mCRC patients.
Collapse
Affiliation(s)
- Jacqueline Duffour
- Digestive Department, CRLC Val d'Aurelle Parc Euromédecine, 34298 Montpellier Cedex 5, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Groeschke J, Solassol I, Bressolle F, Pinguet F. Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate. J Pharm Biomed Anal 2006; 42:362-6. [PMID: 16740372 DOI: 10.1016/j.jpba.2006.04.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2006] [Revised: 04/11/2006] [Accepted: 04/14/2006] [Indexed: 10/24/2022]
Abstract
Amphotericin B and nystatin are two polyene antibiotics that are potent antifungal agents. These drugs are active against most pathogenic fungi like Aspergillus and Candida. Mouthrinses containing these drugs are used for preventive and curative treatment of fungal infections like oral candidiasis, which can cause multiple diseases in cancer patients. Because there were no marketed antifungal mouthrinses available, their preparations were performed at the hospital and town pharmacies. To date, there are no data available on the stability of both these drugs in the form of mouthrinses. Therefore, each mouthrinse had to be prepared extemporaneously. The aim of this study was to investigate the stability of amphotericin B (Fungizone) and nystatin (Mycostatine) in the form of mouthrinses containing 1.4% sodium hydrogen carbonate. The stability of these solutions was tested at different temperatures (4-37 degrees C) with or without electric- or sunlight exposure and in two types of containers (glass and polypropylene) over a 15-day period. The admixtures were also monitored for colour change and pH. Amphotericin B and nystatin were quantified by high-performance liquid chromatography. At 4 degrees C, amphotericin B and nystatin were stable for 15 days in polypropylene. When stored in polypropylene at room temperature, with or without light protection, amphotericin B and nystatin were stable for 3 and 4 days, respectively.
Collapse
Affiliation(s)
- J Groeschke
- Oncopharmacology Laboratory, Val d'Aurelle Anticancer Centre, Parc Euromédecine, Montpellier, France
| | | | | | | |
Collapse
|
39
|
Tu Duy Khiem-El Aatmani A, Senesse P, Reimund JM, Beretz L, Baumann R, Pinguet F. Home Parenteral Nutrition: a direct costs study in the approved centres of Montpellier and Strasbourg. ACTA ACUST UNITED AC 2006; 30:574-9. [PMID: 16733381 DOI: 10.1016/s0399-8320(06)73230-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIM Home Parenteral Nutrition (HPN) is an expensive but relatively cost effective therapy. In France, HPN has been organized around regionally located approved major centers. Few French studies have focused on the economic costs of HPN. The objective of this study was to assess the direct costs of HPN in two approved centers. PATIENTS AND METHODS Included patients and their nurses filled in a questionnaire in a prospective analysis. The questionnaires were complemented by data from the dispensary, the head of the institution's financial administration and different organizations. Cost were calculated according to the national health insurance fund and hospitalisation prices for 2003. RESULTS The direct cost was on average 83 euro per patient per day: 58% for drugs and material, 16% for hospital personnel, 16% for non-institutional caregivers, 4% for patient transportation, 4% for material transportation, and 2% for laboratory tests. The costs reimbursed by the national health insurance fund for laboratory tests, non-institutional caregivers and patient transportation were on average 18 euro per patient per day. Hospital funds provided 78% of the total costs. Daily costs were lower in Strasbourg as compared with Montpellier (62.1 vs 103.3 euro). CONCLUSION The cost of the products administered accounts for the majority of daily costs of home parenteral nutrition which is essentially funded by hospital resources. The lower daily costs per patient in Strasbourg may be related to greater patient independence.
Collapse
|
40
|
Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S, Pinguet F. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit 2006; 27:491-8. [PMID: 16044107 DOI: 10.1097/01.ftd.0000160717.50704.42] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Perception of pain by the patient is frequently one of the early signs preceding a diagnosis of cancer and, later, a sinister sign of disease progression. Among opioid drugs, transdermal fentanyl has been evaluated in the treatment of moderate to severe cancer pain. The objective of this study was to investigate the intra- and interindividual variabilities in pharmacokinetics after fentanyl drug delivery by the transdermal fentanyl patch delivery system in patients with cancer pain. As a first step, a liquid chromatography-mass spectrometry method was developed for the determination of the analgesic fentanyl in human plasma. This method was validated over the concentration range 0.15-100 ng/mL. The study group consisted of 29 inpatients (18 men and 11 women; age range 29-80 years). The initial transdermal fentanyl delivery rate was chosen depending on the patient's analgesic requirements. For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h. For 6 patients, the initial delivery rate was 75-150 microg/h. Two patients received up to 300 microg/h fentanyl delivery rate, and 3 patients received up to 350 microg/h fentanyl delivery rate. Fifteen of the 29 patients received rescue doses of subcutaneous or oral morphine, and 26 patients received paracetamol with codeine (30 mg per os). Blood samples were collected at the following intervals: 2-5, 22-26, or 45-47 hours following fentanyl patch application. The severity of pain experienced by the patient was assessed thrice daily using a visual analogue scale. The study period was 46 days. Large patient-to-patient variations in pharmacokinetic parameters occurred, although intraindividual variability was limited. A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h. From 25 to 100 mug/h fentanyl delivery rate, the pharmacokinetics was linear. At the 2 highest doses, an increase of total clearance was observed (>60 L/h). For the whole group, transdermal fentanyl treatment provided good to excellent pain relief in the majority of patients.
Collapse
MESH Headings
- Acetaminophen/administration & dosage
- Acetaminophen/therapeutic use
- Administration, Cutaneous
- Adult
- Aged
- Aged, 80 and over
- Analgesics, Non-Narcotic/administration & dosage
- Analgesics, Non-Narcotic/therapeutic use
- Analgesics, Opioid/administration & dosage
- Analgesics, Opioid/pharmacokinetics
- Analgesics, Opioid/therapeutic use
- Biological Availability
- Chromatography, High Pressure Liquid/methods
- Chronic Disease
- Codeine/administration & dosage
- Codeine/therapeutic use
- Delayed-Action Preparations
- Dose-Response Relationship, Drug
- Female
- Fentanyl/blood
- Fentanyl/pharmacokinetics
- Fentanyl/therapeutic use
- Humans
- Male
- Middle Aged
- Morphine/administration & dosage
- Morphine/therapeutic use
- Neoplasms/complications
- Pain/drug therapy
- Pain/etiology
- Pain Measurement/methods
- Spectrometry, Mass, Electrospray Ionization/methods
- Time Factors
- Treatment Outcome
Collapse
Affiliation(s)
- Isabelle Solassol
- Onco-pharmacology Department, Pharmacy Service, Val d' Aurelle Anticancer Centre, parc Euromédecine, 34298 Montpellier Cedex 5, France
| | | | | | | | | | | | | |
Collapse
|
41
|
Poujol S, Bressolle F, Duffour J, Abderrahim AG, Astre C, Ychou M, Pinguet F. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer Chemother Pharmacol 2005; 58:292-305. [PMID: 16369821 DOI: 10.1007/s00280-005-0166-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2005] [Accepted: 11/14/2005] [Indexed: 01/11/2023]
Abstract
PURPOSE Irinotecan is extensively metabolized into at least four compounds and previous pharmacokinetic-pharmacodynamic studies have given varying results. We hypothesized that saliva, a noninvasive, safe and painless biological sampling process, could be a good predictor of the behavior of irinotecan and its metabolites. METHODS Thirty-five patients with metastatic digestive cancer were treated with a Folfiri regimen every 2 weeks. The irinotecan-administered dose was 180 mg/m(2); 17 patients participated in a dose-escalating study. Irinotecan and its metabolites (SN-38, SN-38G, APC, NPC) were quantified in plasma and saliva by high-performance liquid chromatography with fluorescence detection. RESULTS The mean irinotecan systemic clearance and steady-state volume of distribution values were 14.3 l/h/m(2) and 211 l/m(2), respectively. The intrapatient variability (22-28%) was far lower than the interindividual variability (33-88%). Age and weight were the two physiological parameters that influenced drug disposition. For irinotecan, SN-38, APC and NPC, similar pharmacokinetic profiles were observed from plasma and saliva data. The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC. Neutropenia, diarrhea and nausea were the main toxicities encountered. From both plasma and saliva data, the percentage decrease in neutrophil count appeared to be related to irinotecan and SN-38 AUCs. CONCLUSIONS All these findings provide a rationale for an individual adaptation of irinotecan dosing. In case of difficult venous access, the titration of irinotecan and of its active metabolite SN-38 in saliva may prove relevant.
Collapse
Affiliation(s)
- Sylvain Poujol
- Oncopharmacology Department, Pharmacy service, Val d'Aurelle Anticancer Centre, parc Euromédecine, Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
42
|
Solassol I, Caumette L, Bressolle F, Garcia F, Thézenas S, Astre C, Culine S, Coulouma R, Pinguet F. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep 2005; 14:1029-36. [PMID: 16142368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023] Open
Abstract
A transdermal therapeutic system (TTS) is recommended for use in chronic cancer pain, particularly in the advanced stages. The aim of this trial was to study intra- and interindividual variabilities in fentanyl transdermal absorption and investigate physiological and clinical parameters that can influence the absorption in patients treated using a TTS for moderate to severe cancer pain. The study group consisted of 108 patients (71 men and 37 women; mean age, 61.3 years) with chronic cancer pain. A total of 507 patches were analysed. The TTSs used to administer fentanyl were removed after a 72-h period. The amount of fentanyl remaining in the patches was determined using a high-performance liquid chromatography method with ultraviolet detection. Depending on the analgesic requirements of the patient, the dose of fentanyl administered by TTS ranged from 25 to 500 microg/h. The study period was 6 months. Large interindividual variability in the amount of remaining fentanyl in the patches occurred. For 58.1% of patches, absorption was 60 to 84%; for 33.2% of them, it was lower; and for 8.8%, it was higher than this range. The intra-individual variability ranged from 2.8 to 75.1%. The bioavailability of fentanyl was statistically different according to patient age. Patients >75 years of age absorbed 50% of the fentanyl during the selected 72-h period, whereas patients <65 years absorbed 66%. Moreover, there is a significant difference in the percentage of absorbed fentanyl according to the type of cancer. The absorption was higher in patients with breast or digestive cancer than in those with lung cancer. Hyperhidrosis, hypertrichosis and the localization of patches on the skin did not influence bioavailability. For the entire group, transdermal fentanyl treatment provided good to excellent pain relief in the majority of patients.
Collapse
Affiliation(s)
- Isabelle Solassol
- Oncopharmacology Laboratory, Val d'Aurelle Anticancer Centre, Parc Euromédecine, Montpellier, France
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Solassol I, Caumette L, Bressolle F, Garcia F, Thézenas S, Astre C, Culine S, Coulouma R, Pinguet F. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep 2005. [DOI: 10.3892/or.14.4.1029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
44
|
Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C, Bressolle F. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol 2004; 53:503-12. [PMID: 15007638 DOI: 10.1007/s00280-003-0761-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2003] [Accepted: 12/18/2003] [Indexed: 11/24/2022]
Abstract
PURPOSE The objective of the present study was to characterize the population pharmacokinetics of melphalan infused over a 24-h period in patients with advanced malignancies. METHODS Enrolled in the study were 64 patients (144 courses). The population pharmacokinetic analysis was performed using NONMEM through the graphical interface Visual-NM. Population characteristics were computed from an initial group of 43 patients (99 courses), and 21 additional patients (45 courses) were used for model validation. With the use of a one-compartment model, the influence of demographic and biological characteristics was examined. The basic parameters were total clearance (CL) and volume of distribution (V). The interoccasion variability was taken into account in the model. The drug exposure was estimated for each patient and correlated with markers of efficacy and toxicity. RESULTS Data analysis was performed using a three-step approach. In step 2, a close relationship was found between creatinine clearance, gender and melphalan CL. The inclusion of this second stage model significantly improved the fit. Melphalan CL was higher in male patients (14.3+/-4.5 l/h per m2) than in female patients (12.3+/-4.5 l/h per m2). CL was also reduced somewhat in patients with decreased creatinine clearance. Large interindividual variability in pharmacokinetic parameters occurred (CL varied from 4.4 to 30.6 l/h per m2). The percentage intrapatient variability in clearance between courses was 25.4%. For determining melphalan AUC in clinical routine from one sample drawn at steady state, Bayesian methodology allowed a more accurate estimation of CL than the classical formula. Neutropenia and thrombocytopenia were the main haematological toxicities encountered; grade 4 was observed in 34 and 22 courses over a total of 144 courses, respectively. No significant relationship between AUC and haematological toxicity was found. In patients with prostatic cancer a weak relationship was observed between the decrease in PSA levels and AUC (P=0.0457), while in patients with ovarian cancer no relationship was found between AUC and CA125 levels. CONCLUSION The population pharmacokinetic approach developed in this study should allow dosage to be individualized in order to decrease toxicity while maintaining good efficacy.
Collapse
Affiliation(s)
- Philippe Mougenot
- Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy, University Montpellier I, 15 Avenue Ch. Flahault, BP 14 491, 34093 Montpellier Cedex 5, France
| | | | | | | | | | | | | |
Collapse
|
45
|
Zurbonsen K, Bressolle F, Solassol I, Aragon PJ, Culine S, Pinguet F. Simultaneous determination of dexamethasone and 6β-hydroxydexamethasone in urine using solid-phase extraction and liquid chromatography: applications to in vivo measurement of cytochrome P450 3A4 activity. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 804:421-9. [PMID: 15081938 DOI: 10.1016/j.jchromb.2004.01.053] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2003] [Revised: 01/26/2004] [Accepted: 01/28/2004] [Indexed: 11/17/2022]
Abstract
It has been demonstrated that the formation of the hydrophilic metabolites of dexamethasone, 6 alpha- and 6 beta-hydroxydexamethasone, correlated with cytochrome P450 (CYP) 3A4 enzyme levels. So, the 6 beta-hydroxydexamethasone/dexamethasone urinary ratio could be a specific marker for human CYP3A4 activity. We have developed a sensitive and specific high-performance liquid chromatographic method for the simultaneous quantification of urinary free dexamethasone and 6 beta-hydroxydexamethasone using 6 alpha-methylprednisolone as internal standard. This method involved a solid phase extraction of the three compounds from urine using Oasis HLB Waters cartridges with an elution solvent of ethyl acetate (2 ml) followed by diethyl ether (1 ml). Separation of the three analytes was achieved within 24 min using a reversed-phase Nova-Pak C(18) analytical column (4 microm, 300 mm x 3.9 mm i.d.). An ultraviolet detector operated at 245 nm was used with a linear response observed from 10 to 100 ng/ml for dexamethasone and from 25 to 1000 ng/ml for 6 beta-hydroxydexamethasone. Obtained from the method validation, inter-assay precision was below 15% and accuracy ranged from 95.7 to 110%. The extraction efficiency of the assay was approximately of 99% and was constant across the calibration range. The lower limit of quantitation was 10 ng/ml for dexamethasone and 25 ng/ml for 6 beta-hydroxydexamethasone; at these levels, precision was below 16% and accuracy was 99-109%. This method was applied to in vivo measure of the CYP3A4 activity.
Collapse
Affiliation(s)
- K Zurbonsen
- Onco-pharmacology Department, Pharmacy Service, Val d'Aurelle Anticancer Centre, Parc Euromédecine, 34298 Montpellier Cedex 5, France
| | | | | | | | | | | |
Collapse
|
46
|
Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, Cupissol D, Pinguet F. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004; 100:1257-61. [PMID: 15022294 DOI: 10.1002/cncr.20100] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND The current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site. METHODS Patients were to receive intravenous gemcitabine at a dose of 1000 mg/m2 over 30 minutes on Days 1 and 8 and docetaxel at a dose of 75 mg/m2 over 1 hour on Day 8 in an outpatient setting. The schedule was repeated every 3 weeks for a maximum of 6 cycles. RESULTS Thirty-five patients were assessable for response and survival. One complete and 13 partial responses were observed. The overall response rate was 40% (95% confidence interval, 28-52%). The median time to disease progression was 2 months (range, 1-4 months). The median overall survival time was 10 months (range, 0-32 months). Toxicity was reported to be manageable. CONCLUSIONS The combination of gemcitabine and docetaxel was found to be active in patients with carcinomas of an unknown primary site. However, the overall outcome of these patients remains poor and novel treatment approaches are required.
Collapse
Affiliation(s)
- Damien Pouessel
- Department of Medical Oncology, Centre Régional de Lutte contre le Cancer Val d'Aurelle, Montpellier, France
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Aragon PJ, Yapi AD, Pinguet F, Chezal JM, Teulade JC, Chapat JP, Blache Y. A Photochemical Approach to Pyridopyrroloquinoline Derivatives as New Potential Anticancer Agents. Chem Pharm Bull (Tokyo) 2004; 52:659-63. [PMID: 15187384 DOI: 10.1248/cpb.52.659] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Indoloquinoline alkaloid cryptolepine and pyridocarbazole alkaloid ellipticine are of great interest because in vitro and in vivo studies revealed their good cytotoxic properties. In order to obtain some biologically active analogs of these compounds, we developped a synthesis based on the photocyclisation of tertiary N-methylated enaminones derived from cyclopentane-1,3-dione and 3 or 6-aminoquinoline. The angular cyclised compounds thus obtained were submitted to Beckmann rearrangement, preceded by the formation of a Z oxime. Finally, the delta-lactame ring was oxidized using 10% palladium/carbon in diphenylether and pyridopyrroloquinolines were obtained. These compounds and the intermediate lactams and cyclopentanopyrroloquinolines were tested in vitro on K 562 cells and A 2780 doxorubicine sensitive and resistant cells. All compounds were less effective than doxorubicine in sensitive cells but their activity wasn't decreased by MDR resistance.
Collapse
Affiliation(s)
- Pierre-Jean Aragon
- Laboratoire de Chimie Organique Pharmaceutique, E.A. 2414, Faculté de Pharmacie, 15 avenue Clarles Flahault, 34060 Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
48
|
Poujol S, Pinguet F, Mougenot P, Malosse F, Fabbro M, Culine S, Astre C, Bressolle F. Quantitation of Melphalan in Human Plasma by Liquid Chromatography and Solid Phase Extraction: Application to Pharmacokinetic Study. J LIQ CHROMATOGR R T 2004. [DOI: 10.1081/jlc-120027101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- S. Poujol
- a Onco‐Pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre , 34298 Montpellier, Montpellier , Cedex , 5 , France
| | - F. Pinguet
- a Onco‐Pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre , 34298 Montpellier, Montpellier , Cedex , 5 , France
| | - P. Mougenot
- a Onco‐Pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre , 34298 Montpellier, Montpellier , Cedex , 5 , France
- b Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy , University of Montpellier I , Montpellier , France
| | - F. Malosse
- a Onco‐Pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre , 34298 Montpellier, Montpellier , Cedex , 5 , France
| | - M. Fabbro
- c Department of Medicine , Val d'Aurelle Anticancer Centre , Montpellier , France
| | - S. Culine
- c Department of Medicine , Val d'Aurelle Anticancer Centre , Montpellier , France
| | - C. Astre
- a Onco‐Pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre , 34298 Montpellier, Montpellier , Cedex , 5 , France
| | - F. Bressolle
- a Onco‐Pharmacology Department, Pharmacy Service , Val d'Aurelle Anticancer Centre , 34298 Montpellier, Montpellier , Cedex , 5 , France
- b Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy , University of Montpellier I , Montpellier , France
| |
Collapse
|
49
|
Poujol S, Pinguet F, Malosse F, Astre C, Ychou M, Culine S, Bressolle F. Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clin Chem 2003; 49:1900-8. [PMID: 14578322 DOI: 10.1373/clinchem.2003.023481] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND We developed gradient HPLC methods for quantification of the antimitotic drug irinotecan (CPT-11) and its four metabolites, SN-38, SN-38 G, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin (APC), and 7-ethyl-10-[4amino-1-piperidino]-carbonyloxycamptothecin (NPC), as the sum of the lactone and carboxylate forms, in human plasma and saliva. Camptothecin was used as internal standard. METHODS The sample pretreatment involved protein precipitation with methanol-acetonitrile (50:50 by volume) followed by acidification with hydrochloric acid to convert the lactone ring-opened form into its lactone form, quantitatively. HPLC separation was performed on a Xterra RP18 column. The excitation wavelength was 370 nm, and the emission wavelength was set at 470 nm for the first 24 min and then at 534 nm for the next 4 min. The stabilities of irinotecan and its four metabolites in plasma, saliva, and acidic extracts were also investigated under various conditions. RESULTS Assays were linear in the tested range of 0.5-1000 micro g/L. For the five analytes, limits of quantification were 0.5 micro g/L in both matrices. The interassay imprecision (as relative standard deviation) was 3.2-14% in plasma and 2.6-5.6% in saliva. Assay recoveries ranged from 92.8% to 111.2% for plasma and 100.1% to 104.1% for saliva. Mean extraction recovery from plasma or saliva was 90%. CONCLUSION The developed assay can be used to determine pharmacokinetic parameters for CPT-11, SN-38, SN-38 G, APC, and NPC in plasma and saliva from patients with metastatic colorectal cancer.
Collapse
Affiliation(s)
- Sylvain Poujol
- Oncopharmacology Department, Pharmacy Service, Val d'Aurelle Anticancer Centre, Parc Euromédecine, 34298 Montpellier, Cedex 5, France
| | | | | | | | | | | | | |
Collapse
|
50
|
Boucaud M, Pinguet F, Culine S, Poujol S, Astre C, Gomeni R, Bressolle F. Modeling plasma and saliva topotecan concentration time course using a population approach. Oncol Res 2003; 13:211-9. [PMID: 12659422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023] Open
Abstract
The purpose of this study was to develop a pharmacokinetic model simultaneously accounting for topotecan concentrations in plasma and saliva. Thirteen patients with metastatic epithelial ovarian cancer received topotecan. During the first and the second courses of treatment, each patient underwent pharmacokinetic evaluation. Data were analyzed using the nonlinear mixed-effect model program. The saliva concentrations were associated to a peripheral compartment while the central compartment described the plasma concentration time course. Thus, a three-compartment model was used; the basic parameters were: total clearance (CL), initial volume of distribution (V1), transfer rate constants (k12/k21 and k13/k31). The interoccasion variability was taken into account in the model. Data analysis was performed using a three-step approach; in step 2, a close relationship was found between creatinine CL and topotecan CL. The inclusion of this second stage model significantly improved the fit. Large interindividual variability in pharmacokinetic parameters occurred (CL varied from 10.4 to 23 L/h) while interoccasion variability was limited (6%). Seven additional courses were used for model validation. A limited sampling strategy using Bayesian estimation based on two sampling times (saliva at 25 min and plasma plus saliva at 8.5 h after the start of infusion) was developed. This study shows that salivary concentrations can be effectively used for drug monitoring.
Collapse
Affiliation(s)
- Maud Boucaud
- Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy, University Montpellier 1, 15 Avenue Ch. Flahault, BP 14 491, 34093 Montpellier Cedex 5, France
| | | | | | | | | | | | | |
Collapse
|